Immunomodulating nanoparticulate composition

摘要

The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.

主权项

1. A method for the treatment of an allergic or inflammatory disease of the lower airways in a mammal, comprising
administering to the mammal a therapeutic effective amount of a pharmaceutical composition via inhalation, comprising a pharmaceutically acceptable polymerized protein-based nanocarrier and as active agent a guanidine phosphodiester cytosine (CpG) oligodeoxynucleotide (ODN), wherein the CpG ODN is a class A CpG ODN, wherein the polymerized protein-based nanocarrier is a gelatin nanoparticle, an albumin nanoparticle, a legumin nanoparticle, a gliadin nanoparticle, a beta-galactoglobuline nanoparticle or a silk protein nanoparticle, and wherein the class A CpG ODN is bound to the surface of the polymerized protein-based nanocarrier reversibly via electrostatic interaction, and wherein the method has a therapeutic effect in the treatment of an allergic or inflammatory disease of the lower airways of at least 4 weeks.